Compare PSQH & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSQH | JSPR |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 26.3M |
| IPO Year | 2021 | 2019 |
| Metric | PSQH | JSPR |
|---|---|---|
| Price | $3.39 | $0.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 38.6K | ★ 360.5K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,685,987.00 | N/A |
| Revenue This Year | $81.45 | N/A |
| Revenue Next Year | $35.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1096.61 | N/A |
| 52 Week Low | $0.36 | $0.32 |
| 52 Week High | $6.94 | $2.69 |
| Indicator | PSQH | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 43.85 |
| Support Level | $0.51 | $0.42 |
| Resistance Level | $5.73 | $0.60 |
| Average True Range (ATR) | 0.35 | 0.05 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 5.61 | 41.17 |
PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.